Molecular mechanisms of anticancer action and cell selectivity ofshort α-helical peptides

Biomaterials

Volumn 35, Issue 5, 2014, Pages 1552-1561

  Chen, Cuixia ^a   Hu, Jing ^a   Zeng, Ping ^a   Pan, Fang ^b   Yaseen, Mohammed ^b   Xu, Hai ^a   Lu, Jian R ^b  

^a CHINA UNIVERSITY OF PETROLEUM   (China)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Anticancer activity; Antimicrobial peptide; Cell apoptosis; Cell selectivity; Membrane permeabilization; Xenograft model

Indexed keywords

ANTICANCER ACTIVITIES; ANTIMICROBIAL PEPTIDE; CELL APOPTOSIS; CELL-SELECTIVITY; MEMBRANE PERMEABILIZATION;

BIOCOMPATIBILITY; BIOLOGICAL MATERIALS; CELL DEATH; CELL MEMBRANES; DRUG INTERACTIONS; FUNCTIONAL MATERIALS; POLYPEPTIDES;

PEPTIDES;

POLYPEPTIDE ANTIBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; XENOGRAFT;

ANTICANCER ACTIVITY; ANTIMICROBIAL PEPTIDE; CELL APOPTOSIS; CELL SELECTIVITY; MEMBRANE PERMEABILIZATION; XENOGRAFT MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DNA PRIMERS; DRUG SCREENING ASSAYS, ANTITUMOR; FLUORESCENT DYES; HELA CELLS; HUMANS; MICE; MICE, NUDE; PEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890159779     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.10.082     Document Type: Article

References (42)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Schweizer F. Cationic amphiphilic peptides with cancer-selective toxicity. Eur J Pharmacol 2009, 625:190-194.
3. Hoskin D.W., Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. BBA-Biomembranes 2008, 1778:357-375.
4. Mader J.S., Hoskin D.W. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs 2006, 15:933-946.
5. Dathe M., Wieprecht T. Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. BBA-Biomembranes 1999, 1462:71-87.
6. Zelezetsky I., Tossi A. Alpha-helical antimicrobial peptides-using a sequence template to guide structure-activity relationship studies. BBA-Biomembranes 2006, 1758:1436-1449.
7. Giangaspero A., Sandri L., Tossi A. Amphipathic alpha helical antimicrobial peptides. Eur J Biochem 2001, 268:5589-5600.
8. Hu J., Chen C., Zhang S., Zhao X., Xu H., Zhao X., et al. Designed antimicrobial andantitumor peptides with high selectivity. Biomacromolecules 2011, 12:3839-3843.
9. Xu H., Wang J., Han S., Wang J., Yu D., Zhang H., et al. Hydrophobic region induced transitions in self-assembled peptide nanostructures. Langmuir 2009, 25:4115-4123.
10. Chen C., Pan F., Zhang S., Hu J., Cao M., Wang J., et al. Antibacterial activities of short designer peptides: a link between propensity for nanostructuring and capacity for membrane destabilization. Biomacromolecules 2010, 11:402-411.
11. Chen C., Hu J., Zhang S., Zhou P., Zhao X., Xu H., et al. Molecular mechanisms of antibacterial and antitumor actions of designed surfactant-like peptides. Biomaterials 2012, 33:592-603.
12. Cruciani R.A., Barker J.L., Zasloff M., Chen H.C., Colamonici O. Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation. Proc Natl Acad Sci U S A 1991, 88:3792-3796.
13. Asthana N., Yadav S.P., Ghosh J.K. Dissection of antibacterial and toxic activity of melittin: a leucine zipper motif plays a crucial role in determining its hemolytic activity but not antibacterial activity. JBiol Chem 2004, 279:55042-55050.
14. Baker M.A., Maloy W.L., Zasloff M., Jacob L.S. Anticancer efficacy of magainin2 and analogue peptides. Cancer Res 1993, 53:3052-3057.
15. Florea A.M., Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 2011, 3:1351-1371.
16. Papo N., Shai Y. Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci 2005, 62:784-790.
17. Brockman H. Lipid monolayers: why use half a membrane to characterize protein-membrane interactions?. Curr Opin Struct Biol 1999, 9:438-443.
18. Marsh D. Lateral pressure in membranes. BBA-Rev Biomembranes 1996, 1286:183-223.
19. Hendrich A.B., Michalak K. Lipids as a target for drugs modulating multidrug resistance of cancer cells. Curr Drug Targets 2003, 4:23-30.
20. Kerr J.F.R., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26:239-257.
21. Oberhammer F.A., Hochegger K., Fröschl G., Tiefenbacher R., Pavelka M. Chromatin condensation during apoptosis is accompanied by degradation of laminA+B, without enhanced activation of cdc2 kinase. JCell Biol 1994, 126:827-837.
22. Walker P.R., Kokileva L., Leblanc J., Sikorska M. Detection of the initial stages of DNA fragmentation in apoptosis. Biotechniques 1993, 15:1032-1040.
23. Bortner C.D., Oldenburg N.B.E., Cidlowski J.A. The role of DNA fragmentation in apoptosis. Trends Cell Biol 1995, 5:21-26.
24. Saraste A., Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 2000, 45:528-537.
25. Gourlay C.W., Ayscough K.R. The actin cytoskeleton: a key regulator of apoptosis and ageing?. Nat Rev Mol Cell Biol 2005, 6:583-589.
26. Rangel M., Prado M.P., Konno K., Naoki H., Freitas J.C., Machado-Santelli G.M., et al. Cytoskeleton alterations induced by Geodia corticostylifera depsipeptides in breast cancer cells. Peptides 2006, 27:2047-2057.
27. Ndozangue-Touriguine O., Hamelin J., Bréard J. Cytoskeleton and apoptosis. Biochem Pharmacol 2008, 76:11-18.
28. Gourlay C.W., Ayscough K.R. Arole for actin in aging and apoptosis. Biochem Soc Trans 2005, 33:1260-1264.
29. Green D.R., Reed J.C. Mitochondria and apoptosis. Science 1998, 281:1309-1312.
30. Desagher S., Martinou J.C. Mitochondria as the central control point of apoptosis. Trends Cell Biol 2000, 10:369-377.
31. Li H., Kolluri S.K., Gu J., Dawson M.I., Cao X., Hobbs P.D., et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 2000, 289:1159-1164.
32. Ly J.D., Grubb D.R., Lawen A. The mitochondrial membrane potential (δψ m) in apoptosis; an update. Apoptosis 2003, 8:115-128.
33. Smiley S.T., Reers M., Mottola-Hartshorn C., Lin M., Chen A., Smith T.W., et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci U S A 1991, 88:3671-3675.
34. Heiskanen K.M., Bhat M.B., Wang H.W., Ma J., Nieminen A.L. Mitochondrial depolarization accompanies cytochrome c release during apoptosis in PC6 cells. JBiol Chem 1999, 274:5654-5658.
35. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-489.
36. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science 1998, 281:1305-1308.
37. Kavurma M., Khachigian L. Signaling and transcriptional control of Fas ligand gene expression. Cell Death Differ 2003, 10:36-44.
38. Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002, 296:1635-1636.
39. Kuwana T., Smith J.J., Muzio M., Dixit V., Newmeyer D.D., Kornbluth S. Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c. JBiol Chem 1998, 273:16589-16594.
40. De Groote D., Zangerle P.F., Gevaert Y., Fassotte M.F., Beguin Y., Noizat-Pirenne F., et al. Direct stimulation of cytokines (IL-1β, TNF-β, IL-6, IL-2, IFN-γ and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine 1992, 4:239-248.
41. Feghali C.A., Wright T.M. Cytokines in acute and chronic inflammation. Front Biosci 1997, 2:d12-26.
42. Makovitzki A., Fink A., Shai Y. Suppresion of human solid tumor growth in mice by intratumor and systemic inocation of histidine-rich and pH-dependent host defense-lie lytic peptides. Cancer Res 2009, 69:3458-3463.